Presentation is loading. Please wait.

Presentation is loading. Please wait.

ASCO G.U. 2014 Lawrence H. Einhorn.

Similar presentations


Presentation on theme: "ASCO G.U. 2014 Lawrence H. Einhorn."— Presentation transcript:

1 ASCO G.U. 2014 Lawrence H. Einhorn

2 TOPICS Testis cancer – nothing new Bladder cancer Renal cell cancer
July 1, 2014 JCO (correspondence) – Albany and Einhorn: Pitfalls in low level elevations of AFP Bladder cancer PD-L1 Renal cell cancer Ranking of treatment options Nivolumab PD-1 Prostate cancer Adjuvant Docetaxel Enzalutamide

3 Inhibition of PD-L1 by MPDL3280A<br />leads to clinical activity in<br />patients with metastatic urothelial bladder cancer (UBC)

4 MPDL 3280A PD-L1 I IN METASTATIC BLADDER CA
65 patients entered 71% received 2 or more prior therapies 17 of 65 (26%) response rate, but 13 of 30 (43%) if PD-L1 positive (2+ or 3+) by IHC, including 2 C.R.s Genentech phase II study to enroll (!!) patients

5 Renal Cell Cancer

6 Algorithm for Clear Cell RCC Therapy
Presented By Michael Atkins at 2014 ASCO Annual Meeting

7 Presented By Robert Motzer at 2014 ASCO Annual Meeting
Nivolumab for metastatic renal cell <br />carcinoma (mRCC): results of a randomized, dose-ranging phase II trial Presented By Robert Motzer at 2014 ASCO Annual Meeting

8 Presented By Robert Motzer at 2014 ASCO Annual Meeting
Phase II study design Presented By Robert Motzer at 2014 ASCO Annual Meeting

9 Key inclusion criteria
Presented By Robert Motzer at 2014 ASCO Annual Meeting

10 NIVOLUMAB IN METASTATIC RENAL CELL CA
168 patients entered; all received prior therapy and 70% 2 or more including VEGF TKIs (98%) MTOR inhibitors (38%) and immunotherapy (24%) 35 of 168 (21%) response rate; 19 of these 35 (54%) remissions were 12+ month duration

11 Presented By Robert Motzer at 2014 ASCO Annual Meeting
Overall survival Presented By Robert Motzer at 2014 ASCO Annual Meeting

12 PROSTATE CANCER

13 ASCO 2004, abstracts 3 and 4<br />mCRPC
2 months improvement in OS

14 <br /><br />E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

15 Men with Metastatic Hormone Sensitive Prostate Cancer
E3805 – CHAARTED Treatment ADT + Docetaxel x 6 cycles Men with Metastatic Hormone Sensitive Prostate Cancer ADT Alone ADT allowed up to 120 days prior to randomization No Intermittent ADT allowed Primary Endpoint: Overall Survival Secondary Endpoints: PSA response rate, Time to progression, Toxicity QOL.

16 Primary endpoint: Overall survival
13.6 months Primary endpoint: Overall survival

17 Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Secondary Endpoints Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

18 Drugs that prolong OS for CRPC
Presented By Michael Morris at 2014 ASCO Annual Meeting

19 Men with Metastatic Castration Resistant Prostate Cancer
PREVAIL– Study Design Enzalutamide N=872 Men with Metastatic Castration Resistant Prostate Cancer Chemo-naïve N= 1717 Placebo N=845 Co-Primary Endpoint: Radiographic PFS Overall Survival

20 Presented By Andrew Armstrong at 2014 ASCO Annual Meeting
PREVAIL Was Halted at the Interim Analysis for Significant Benefit with Enzalutamide Presented By Andrew Armstrong at 2014 ASCO Annual Meeting

21 Presented By Andrew Armstrong at 2014 ASCO Annual Meeting
Enzalutamide Prolonged Radiographic <br />Progression-Free Survival Presented By Andrew Armstrong at 2014 ASCO Annual Meeting

22 Enzalutamide Reduced Risk of Death by 29%
Presented By Andrew Armstrong at 2014 ASCO Annual Meeting

23 Enzalutamide Delayed Time to PSA Progression
Presented By Andrew Armstrong at 2014 ASCO Annual Meeting

24

25 SUMMARY Testis cancer Bladder cancer Renal cell cancer Castrate resistant prostate cancer


Download ppt "ASCO G.U. 2014 Lawrence H. Einhorn."

Similar presentations


Ads by Google